Sirolimus may be an effective treatment for patients with persistent cutaneous sarcoidosis. In a small clinical trial, 7 of 10 patients treated with sirolimus via oral solution had improvements in ...
LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined ...
Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial Although all authors ...
Aadi Bioscience is a biotech company focused on a nanoliposomal encapsulation of the mTOR inhibitor sirolimus. Their drug, nab-sirolimus, has been approved for the treatment of PEComa, a rare soft ...
Fulvestrant, the selective estrogen receptor degrader and PI3K inhibitors, such as alpelisib, have demonstrated efficacy in patients with HR+ PI3K-mutated breast cancer; however, resistance still ...
Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma This investigator-initiated, phase II, multicenter, single-arm trial enrolled patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results